FindTrial
Sign In

An Observational study comparing the Efficacy and Safety between Intralesional Triamcinolone Acetonide(4mg/ml) And Modified Kligmans Formula in Treatment of Melasma

An observational study of the Efficacy and Safety between Intralesional Triamcinolone Acetonide(4mg/ml) And Modified Kligmans Formula in Treatment of Melasma - Nil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060279
Enrollment
60
Registered
2023-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

Intervention1: INTRALESIONAL TRIAMCINOLONE(4mg/ml) IN MELASMA: MODIFIED KLIGMANS FORMULA IN MELASMA Intervention2: Intralesional Triamcinolone Acetonide (4mg/ml): In treatment of melasma 4weeks once

Sponsors

Aishwarya N
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed and consenting patients with melasma

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating mothers 2. Patients with other facial hyperpigmented dermatoses, telangiectasia or Autoimmune disorder 3. Non consenting patients 4. Patients with unrealistic expectations 5. Patients who are already on treatment will be included after a wash out period of 1 month

Design outcomes

Primary

MeasureTime frame
1.To study safety and efficacy of Modified Kligmans formula in treatment of Melasma. 2. To study the efficacy and safety of Intralesional Triamcinolone Acetonide(4mg/ml) in treatment of Melasma 3. To compare safety and efficacy of the above two in treatment of melasmaTimepoint: 2 months—

Secondary

MeasureTime frame
Melasma Assessment Severity Index and dermoscopic findingsTimepoint: 2 months—

Countries

India

Contacts

Public ContactAishwarya N

DR B R Ambedkar Medical College and Hospitals

drshilpark@gmail.com9663384483

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026